Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality.
There is a need for a marker associated with HCC progression. A disintegrin and metalloprotease
(ADAMs) family proteins have a lot of functions in cell adhesion, migration, proteolysis and
Aims: The aim of the study was to investigate the relation between ADAM 10 gene single nucleotide
polymorphisms (SNPs) and HCC progression.
Methods: This study involved 201 cases divided: Group I (67 HCC patients), Group II (67 cirrhotic
patients), Group III (67 control). Each group was subjected to laboratory investigations: (CBC,
blood sugar, kidney and liver function, viral markers, alpha fetoprotein), imaging: (abdominal ultrasonography,
and triphasic C.T) and ADAM 10 gene polymorphism (rs 653765, rs 383902) detection
by real – time PCR.
Results: There was a statistically significant difference in the frequency and genotyping of
ADAM10 SNPs in HCC patients in comparison to cirrhotic and control groups [the frequency of rs
653765 genotypes (p=0.015) and model (p=0.013)]; likewise, the frequency of rs 383902 genotypes
(p<0.001) and model (p=0.001)). Also, there was a statistically significant association between
different SNP rs 383902 genotype with CLIP stages (p=0.02) and with VISUM stages
Conclusion: ADAM-10 is overexpressed in HCC patients and involved in HCC progress. These
findings highlight that ADAM inhibitor may be used as therapeutic goals in the treatment of HCC.